;

Egypt Immuno-Oncology Research Review Issue 8

In this issue:
  -  First-line serplulimab + chemotherapy in extensivestage SCLC
  -  Nivolumab + ipilimumab ±SBRT for advanced MCC
  -  Adjuvant atezolizumab for RCC at increased recurrence risk postresection
  -  Adjuvant pembrolizumab in resected stage IIB or IIC melanoma
  -  Neoadjuvant cemiplimab for stage II–IV cutaneous SCC
  -  First-line avelumab for PD-L1- positive metastatic or locally advanced urothelial cancer
  -  Pembrolizumab in MSI-high or mismatch repair deficient cancers
  -  Nivolumab + low-dose ipilimumab in pretreated MSI-high/mismatch repair-deficient metastatic CRC
  -  QOL for persistent immunerelated adverse events after ICI cessation
  -  Nivolumab-ipilimumabcabozantinib triplet for previously untreated advanced RCC
  -  CV events in ICI recipients

Download PDF Subscribe